An additional study externally validating this CT PEER measurement method found a similarly high sensitivity of 93% for distinguishing chRCC from oncocytoma regardless of tumour CD117 status on pathology evaluation and a sensitivity of 97% for identifying chRCC in the CD117 positive tumour subset.10 This evidence concerns the gene KIT and oncocytic adenoma.